Arthritis

2024 OREF Clinical Research Award Celebrates Study of Local Gene Therapy to Treat Osteoarthritis

Retrieved on: 
Friday, February 2, 2024

ROSEMONT, Ill. , Feb. 2, 2024 /PRNewswire/ -- The 2024 Orthopaedic Research and Education Foundation (OREF) Clinical Research Award was presented to Christopher H. Evans, PhD (Mayo Clinic), Steven C. Ghivizzani, PhD (University of Florida), and Paul D. Robbins, PhD (University of Minnesota), for their research on local gene therapy for osteoarthritis (OA).

Key Points: 
  • ROSEMONT, Ill. , Feb. 2, 2024 /PRNewswire/ -- The 2024 Orthopaedic Research and Education Foundation (OREF) Clinical Research Award was presented to Christopher H. Evans, PhD (Mayo Clinic), Steven C. Ghivizzani, PhD (University of Florida), and Paul D. Robbins, PhD (University of Minnesota), for their research on local gene therapy for osteoarthritis (OA).
  • Together, the team spearheaded the research from a laboratory concept to human clinical trials over the course of 30 years.
  • The OREF Award recognizes outstanding clinical research related to musculoskeletal disease or injury.
  • Evans, Ghivizzani and Robbins co-founded an arthritis gene therapy startup company, Genascence Corporation, which will help fund future clinical trials.

Global Market for Animal Therapeutics and Diagnostics Poised to Reach $81.2 Billion by 2028 - BCC Research Analyst

Retrieved on: 
Thursday, January 25, 2024

BOSTON, Jan. 25, 2024 /PRNewswire/ -- The Global Markets for Animal Therapeutics and Diagnostics are undergoing a transformative phase, driven by a surge in awareness and investment in animal health. This dynamic market encompasses a broad spectrum of therapeutic interventions and diagnostic solutions designed to enhance the well-being of animals worldwide. As the demand for advanced healthcare for companion and livestock animals intensifies, the global market is poised to reach $81.2 billion by 2028. This introduction explores the trends, innovations, and market dynamics propelling the growth of animal therapeutics and diagnostics on a global scale. From breakthrough treatments to cutting-edge diagnostic technologies, this market is evolving to meet the increasing expectations for animal welfare and healthcare standards.

Key Points: 
  • With a Steady 5.9% CAGR, the Market for Animal Therapeutics and Diagnostics is Set to Expand from $61.0 Billion in 2023 to$81.2 Billion by 2028.
  • As the demand for advanced healthcare for companion and livestock animals intensifies, the global market is poised to reach $81.2 billion by 2028.
  • This introduction explores the trends, innovations, and market dynamics propelling the growth of animal therapeutics and diagnostics on a global scale.
  • This comprehensive report offers an extensive overview of the global animal therapeutics and diagnostics market, leveraging 2022 as the base year and forecasting the compound annual growth rate (CAGR) from 2023 to 2028.

ProleevaMax Unleashes Innovative Organic Supplement Targeting Arthritic Pain: A Holistic Approach to Pain Management

Retrieved on: 
Friday, January 12, 2024

FORT LAUDERDALE, Fla., Jan. 12, 2024 /PRNewswire-PRWeb/ -- ProleevaMax, a trailblazer in organic health solutions, proudly announces the launch of its flagship supplement, a revolutionary product designed to address arthritic pain specifically. This unique formulation takes a holistic approach to pain management, providing a natural solution to chronic discomfort.

Key Points: 
  • ProleevaMax launches holistic, organic supplements for arthritic pain, redefining pain management with innovation and natural relief.
  • We are excited to introduce a holistic pain medicine that addresses arthritic pain at its roots.
  • ProleevaMax's flagship supplement stands out in the realm of arthritic pain and supplements by offering a holistic pain medicine that goes beyond traditional approaches.
  • The product's formulation is meticulously crafted to provide relief from arthritic pain while addressing the root causes, setting a new standard in holistic pain management.

United States Pain Management Therapeutics Market Report 2023: Neurostimulation and Online Pharmacies Surges - Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 9, 2024

The "United States Pain Management Therapeutics Market, Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Pain Management Therapeutics Market, Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Pain Management Therapeutics Market in the United States demonstrates robust growth, projected to achieve a market size of US$ 33.71 Billion by 2030.
  • The report highlights a substantial investment in research and development by major pharmaceutical organizations to produce advanced pain management solutions.
  • Opioids continue to hold the largest share in the United States pain management drug market.

Dr. Gundry, Regenerative Medicine Expert, Unveils Groundbreaking Insights in New Book, "Gut Check: Unleash the Power of Your Microbiome to Reverse Disease and Transform Your Mental, Physical and Emotional Health"

Retrieved on: 
Tuesday, January 9, 2024

LOS ANGELES, Jan. 9, 2024 /PRNewswire/ -- While science and medicine have certainly come a long way in the last 2,400 years, emerging science has proven Hippocrates was right all those years ago – all disease begins in the gut. This means our gut microbiome, including gut bacteria and the integrity of our gut lining, strongly affects our overall health. When our microbiome is out of balance, it affects our immune system, hormone levels, mental health, longevity, and our risk for developing autoimmune, heart, and neurodegenerative diseases, as well as arthritis, diabetes, and cancer.

Key Points: 
  • This means our gut microbiome, including gut bacteria and the integrity of our gut lining, strongly affects our overall health.
  • When our microbiome is out of balance, it affects our immune system, hormone levels, mental health, longevity, and our risk for developing autoimmune, heart, and neurodegenerative diseases, as well as arthritis, diabetes, and cancer.
  • Revealing the unimaginably complex and intelligent ecosystem controlling our health, Gut Check teaches us how to heal our gut to prevent and reverse every type of disease.
  • To learn more about the book's highlights, watch his recent "Gut Check: Sneak Preview" episode on the Dr. Gundry Podcast YouTube channel .

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Urgent Voluntary Recall of D&D Commodities Ltd.

Retrieved on: 
Thursday, January 4, 2024

D&D Commodities Ltd. is taking immediate action to remove the product from retail distribution centers and to fully investigate the cause.

Key Points: 
  • D&D Commodities Ltd. is taking immediate action to remove the product from retail distribution centers and to fully investigate the cause.
  • Consumers with questions may contact D&D Commodities Ltd. at 1-218-991-8015, Monday through Friday, 8:00 am to 5:00 pm CST.
  • D&D Commodities Ltd. has chosen to issue a voluntary recall of this product and is committed to providing high-quality, safe products for wild and domesticated birds and the people who love them.
  • This is a voluntary recall being conducted in cooperation with the FDA.

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Retrieved on: 
Thursday, January 4, 2024

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Military Makeover with Montel® Honors the Resilience and Service of Jared Bowman and Family in Upcoming Season

Retrieved on: 
Thursday, January 4, 2024

STATESVILLE, N.C., Jan. 4, 2024 /PRNewswire/ -- Military Makeover with Montel® along with Official Non-Profit Partner, Purple Heart Homes, proudly announces the next veteran recipient of a home makeover, Jared Bowman and his deserving family. Jared Bowman, a 35-year-old native of Raleigh, North Carolina, embodies resilience, dedication, and commitment to his country and loved ones.

Key Points: 
  • Jared Bowman, a 35-year-old native of Raleigh, North Carolina, embodies resilience, dedication, and commitment to his country and loved ones.
  • "Each season of Military Makeover is an opportunity to honor our heroes, weaving stories of resilience and transformation," says Scott Moss, President & EVP of Programming for Military Makeover and BrandStar Entertainment.
  • "Jared and his family could not be more deserving, and I am excited to see this renovation complete.
  • Military Makeover with Montel is honored to feature the Bowman Family as the recipients of this season's home makeover.

AbelZeta Announces Formation of Scientific Advisory Board to Support Inflammatory and Immunological Diseases

Retrieved on: 
Wednesday, January 3, 2024

These four industry experts are distinguished scientific leaders with vast experience in the autoimmune disease field."

Key Points: 
  • These four industry experts are distinguished scientific leaders with vast experience in the autoimmune disease field."
  • Members of the SAB include:
    Peter Lipsky, M.D., served on the Board of Directors of the American College of Rheumatology.
  • She was President of the American College of Rheumatology, President of the Henry Kunkel Society, and Chair of the Scientific Advisory Board of the Lupus Research Alliance.
  • "AbelZeta is advancing promising new therapies for inflammatory and immunological diseases through innovative cell therapy platforms that provide custom-tailored treatment for each individual patient.